NASDAQ:IMGN
Delisted
ImmunoGen Stock News
$31.23
+0 (+0%)
At Close: May 08, 2024
ImmunoGen (IMGN) Q1 2022 Earnings Call Transcript
05:30pm, Friday, 06'th May 2022 The Motley Fool
IMGN earnings call for the period ending March 31, 2022.
ImmunoGen, Inc. (IMGN) CEO Mark Enyedy on Q1 2022 Results - Earnings Call Transcript
01:12pm, Friday, 06'th May 2022
ImmunoGen, Inc. (NASDAQ:IMGN ) Q1 2022 Results Conference Call May 6, 2022 8:00 AM ET Company Participants Courtney O'Konek - Senior Director, Corporate Communications Mark Enyedy - President, CEO Ann
ImmunoGen (IMGN) Reports Q1 Loss, Tops Revenue Estimates
11:45am, Friday, 06'th May 2022 Zacks Investment Research
ImmunoGen (IMGN) delivered earnings and revenue surprises of 52.38% and 56.39%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
ImmunoGen (IMGN) Reports Q1 Loss, Tops Revenue Estimates
09:03am, Friday, 06'th May 2022
ImmunoGen (IMGN) delivered earnings and revenue surprises of 52.38% and 56.39%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
ImmunoGen: Way Beyond SORAYA
10:35am, Sunday, 10'th Apr 2022
The market recently discounted ImmunoGen due to its expectation of Mirvetuximab's SORAYA data.
Is ImmunoGen Stock a Bargain After Dropping 39%?
03:23pm, Friday, 01'st Apr 2022 The Motley Fool
It takes more than a price drop to make a bargain.
Is ImmunoGen Stock a Bargain After Dropping 39%?
11:23am, Friday, 01'st Apr 2022
It takes more than a price drop to make a bargain.
ImmunoGen (IMGN) Files BLA for Lead Drug in Ovarian Cancer
03:51pm, Wednesday, 30'th Mar 2022 Zacks Investment Research
ImmunoGen (IMGN) seeks accelerated approval from the FDA for its lead candidate, mirvetuximab soravtansine, in previously treated platinum-resistant ovarian cancer. This pushes the stock price up.
ImmunoGen (IMGN) Files BLA for Lead Drug in Ovarian Cancer
01:33pm, Wednesday, 30'th Mar 2022
ImmunoGen (IMGN) seeks accelerated approval from the FDA for its lead candidate, mirvetuximab soravtansine, in previously treated platinum-resistant ovarian cancer. This pushes the stock price up.
The Daily Biotech Pulse: Sanofi-IGM Ink Antibody Drug Collaboration; NeoGenomics Sinks On CEO Departure, Q1 Warning; Decision Day For Akebia
11:41am, Tuesday, 29'th Mar 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Pfizer Announces Positive Results From Second Late-Stage Study Of Ulcerative Colitis Drug
Pfizer, Inc.
Why Coinbase and Immunogen Led the Nasdaq Lower Monday
07:00pm, Monday, 21'st Mar 2022 The Motley Fool
Markets were jittery following troubling comments from Fed chair Jerome Powell.
Why Coinbase and Immunogen Led the Nasdaq Lower Monday
03:00pm, Monday, 21'st Mar 2022
Markets were jittery following troubling comments from Fed chair Jerome Powell.
Benzinga's Top Ratings Upgrades, Downgrades For March 21, 2022
02:09pm, Monday, 21'st Mar 2022 Benzinga
Upgrades
According to B. Riley Securities, the prior rating for BRT Apartments Corp (NYSE:BRT) was changed from Neutral to Buy. BRT Apartments earned $0.41 in the fourth quarter, compared to $0.33 in
Why Are ImmunoGen Shares Trading Lower Today
12:26pm, Monday, 21'st Mar 2022 Benzinga
ImmunoGen Inc (NASDAQ: IMGN) shared full results from the SORAYA trial evaluating mirvetuximab in folate receptor alpha (FRα)-high platinum-resistant ovarian cancer patients, previously treated wi
Why Are ImmunoGen Shares Trading Lower Today
08:28am, Monday, 21'st Mar 2022
ImmunoGen Inc (NASDAQ: IMGN) shared full results from the SORAYA trial evaluating mirvetuximab in folate receptor alpha (FRα)-high platinum-resistant ovarian cancer patients, previously treated wi
